Advances in the treatment of multiple myeloma

Speaker: Philippe Moreau

P. Moreau discusses the practice changing findings in multiple myeloma presented at ASCO 2016 Annual Meeting: lenalidomide in maintenance setting improved overall survival, addition of daratumumab to bortezomib and dexamethasone in relapsed or refractory setting led to longer duration of response and progression-free survival, he emphasize the role of upfront stem cell transplantation.

Discussion Points

  1. Rationale for the study
  2. Key study findings
  3. Practice perspective

Abstract 8001: Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).                                                                          

Abstract  LBA4: Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Abstract 8000: Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).